Gavin Giovannoni

Strategies to target progression in MS 2:23
Strategies to target progression in MS
Gavin Giovannoni • 1 Mar 2022
Biology or poor trial design…What underlies remyelination trial failures in MS? 4:50
Biology or poor trial design…What underlies remyelination trial failures in MS?
Gavin Giovannoni • 1 Mar 2022
CLASSIC-MS: 8-10 year follow-up of ORACLE trial shows long-term efficacy of cladribine for MS 3:57
CLASSIC-MS: 8-10 year follow-up of ORACLE trial shows long-term efficacy of cladribine for MS
Gavin Giovannoni • 1 Mar 2022
The challenges of screening and diagnosing multiple sclerosis 2:22
The challenges of screening and diagnosing multiple sclerosis
Gavin Giovannoni • 1 Mar 2022
COVID-19 outcomes in patients with relapsing MS receiving cladribine 2:22
COVID-19 outcomes in patients with relapsing MS receiving cladribine
Gavin Giovannoni • 1 Mar 2022
The problem with defining types of MS 3:10
The problem with defining types of MS
Gavin Giovannoni • 19 Oct 2020
The benefits of treatments with minimal scientific basis in MS 1:51
The benefits of treatments with minimal scientific basis in MS
Gavin Giovannoni • 19 Oct 2020
Lessons to be learned from the laquinimod trial for MS 1:50
Lessons to be learned from the laquinimod trial for MS
Gavin Giovannoni • 19 Oct 2020
Future avenues of MS treatment 2:04
Future avenues of MS treatment
Gavin Giovannoni • 19 Oct 2020
The content of VJNeurology is intended for healthcare professionals